S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Albireo Pharma (ALBO) Stock Forecast, Price & News

+0.65 (+3.24%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
314,903 shs
Average Volume
292,215 shs
Market Capitalization
$400.79 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

Albireo Pharma logo

About Albireo Pharma

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$7.65 per share


Net Income
$-34.03 million
Pretax Margin




Free Float
Market Cap
$400.79 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.20 out of 5 stars

Medical Sector

361st out of 1,424 stocks

Pharmaceutical Preparations Industry

145th out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

Is Albireo Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma
or view top-rated stocks.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Albireo Pharma

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.02) by $0.17. Albireo Pharma had a negative trailing twelve-month return on equity of 73.93% and a negative net margin of 72.02%. During the same period last year, the firm posted ($2.29) EPS.
View Albireo Pharma's earnings history

What price target have analysts set for ALBO?

3 brokerages have issued 12-month price targets for Albireo Pharma's shares. Their forecasts range from $66.00 to $80.00. On average, they anticipate Albireo Pharma's stock price to reach $72.67 in the next twelve months. This suggests a possible upside of 251.0% from the stock's current price.
View analysts' price targets for Albireo Pharma
or view top-rated stocks among Wall Street analysts.

Who are Albireo Pharma's key executives?
Albireo Pharma's management team includes the following people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 59, Pay $1.1M)
  • Mr. Simon Nicolas Reade Harford, CFO & Treasurer (Age 61, Pay $687.78k)
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 70, Pay $710.69k)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Dr. Jan P. Mattsson Ph.D., Chief Scientific Officer, MD (Sweden) & Co-Founder (Age 58)
  • Ms. Joan Connolly, Chief Technology Officer
  • Mr. Jason G. Duncan, Chief Legal Officer, Gen. Counsel & Sec. (Age 48) (LinkedIn Profile)
  • Ms. Michelle Graham, Chief HR Officer (Age 55)
  • Dr. Kristina Torfgard, VP & Global Project Head
  • Ms. Pamela Stephenson M.P.H., Chief Commercial Officer (Age 54) (LinkedIn Profile)
What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.94%), Chicago Capital LLC (5.23%), Vanguard Group Inc. (5.05%), State Street Corp (4.69%), Decheng Capital Management III Cayman LLC (2.68%) and Prosight Management LP (2.48%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends for Albireo Pharma

Which major investors are selling Albireo Pharma stock?

ALBO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Platinum Investment Management Ltd., Citigroup Inc., Prosight Management LP, Privium Fund Management B.V., BlackRock Inc., and Blair William & Co. IL. Company insiders that have sold Albireo Pharma company stock in the last year include Jason Duncan, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Ronald Harold Wilfred Cooper, and Simon NR Harford.
View insider buying and selling activity for Albireo Pharma
or view top insider-selling stocks.

Which major investors are buying Albireo Pharma stock?

ALBO stock was acquired by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, Nicholas Investment Partners LP, Chicago Capital LLC, Prudential Financial Inc., MAI Capital Management, Endurant Capital Management LP, Vanguard Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Albireo Pharma
or or view top insider-buying stocks.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $20.70.

How much money does Albireo Pharma make?

Albireo Pharma has a market capitalization of $400.79 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34.03 million in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Albireo Pharma have?

Albireo Pharma employs 130 workers across the globe.

When was Albireo Pharma founded?

Albireo Pharma was founded in 2003.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is www.albireopharma.com.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at [email protected], or via fax at 203-796-5001.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.